5:30 PM
 | 
Apr 28, 2014
 |  BC Extra  |  Clinical News

Athersys falls on MultiStem UC miss

Athersys Inc. (NASDAQ:ATHX) fell $1.40 (51%) to $1.33 on Monday after reporting interim data from 88 patients showing a single IV infusion of MultiStem missed the co-primary endpoints in a Phase II trial to treat...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >